Lixte Biotechnology shareholders approve reverse stock split up to 1-for-10

On May 26, 2023, the Company held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, the Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation to combine the Company’s outstanding shares of common stock into a lesser number of outstanding shares (the “Reverse Stock Split”) at a specific ratio up to a maximum of 1-for-10 split, with the exact ratio to be determined by the Company’s Board of Directors (the “Board”), in its sole discretion. Set forth below are the final voting results for the Reverse Stock Split Proposal: Proposal 1 – Approval of Granting the Board discretionary authority to effectuate the Reverse Stock Split. Stockholders of the Company approved granting the Board authority to effectuate the Reverse Stock Split. The voting results were as follows, based on 16,659,093 shares of common stock outstanding and entitled to vote: Votes For Votes Against Abstentions Broker Non-Votes 11,122,681 577,844 2,841 275